Embecta Corp.
HealthcareNASDAQ:EMBC · NASDAQ Global Select
+$0.02 today
Vol 1.54M · Avg 1.92M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.0B of revenue converted into $111.9M of net income for the selected period. Gross margin is 62.2% and net margin is 10.1%, showing how much revenue survives after costs and taxes. EPS is $1.90, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B -3.8% | $1.1B +0.2% | $1.1B -0.8% | $1.1B -3.0% | $1.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $400.9M +1.7% | $394.2M +6.3% | $370.9M +4.6% | $354.6M -2.8% | $365.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $679.5M -6.8% | $728.9M -2.8% | $749.9M -3.2% | $774.9M -3.1% | $800.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 62.9% -2.0pp | 64.9% -2.0pp | 66.9% -1.7pp | 68.6% -0.1pp | 68.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $21.5M -72.7% | $78.8M -7.5% | $85.2M +31.1% | $65.0M +3.2% | $63.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $331.4M -9.2% | $365.1M +7.0% | $341.3M +15.8% | $294.8M +22.7% | $240.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $350.2M -36.9% | $554.7M +6.6% | $520.3M +31.1% | $396.8M +28.8% | $308.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $51.1M +20.2% | $42.5M +30.0% | $32.7M +3.2% | $31.7M -16.6% | $38.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $294.7M +48.1% | $199.0M -18.9% | $245.4M -26.6% | $334.5M -37.2% | $533.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 27.3% +9.6pp | 17.7% -4.2pp | 21.9% -7.7pp | 29.6% -16.1pp | 45.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $329.3M +89.0% | $174.2M -24.1% | $229.6M -39.3% | $378.1M -23.2% | $492.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 30.5% +15.0pp | 15.5% -5.0pp | 20.5% -13.0pp | 33.5% -8.8pp | 42.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $107.3M -4.5% | $112.3M +5.0% | $107.0M +131.6% | $46.2M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$193.0M -48.5% | -$130.0M -4.9% | -$123.9M -2.0% | -$121.5M -4150.0% | $3.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $136.3M +208.4% | $44.2M -58.2% | $105.7M -58.8% | $256.6M -48.2% | $495.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 12.6% +8.7pp | 3.9% -5.5pp | 9.4% -13.3pp | 22.7% -19.8pp | 42.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $40.9M +219.9% | -$34.1M -196.6% | $35.3M +7.0% | $33.0M -58.8% | $80.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $95.4M +21.8% | $78.3M +11.2% | $70.4M -68.5% | $223.6M -46.1% | $414.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.8% +1.9pp | 7.0% +0.7pp | 6.3% -13.5pp | 19.8% -15.8pp | 35.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +20.6% | $1 +10.6% | $1 -68.6% | $4 -46.4% | $7 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +20.9% | $1 +9.8% | $1 -68.6% | $4 -46.8% | $7 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $58.3M -0.2% | $58.4M +2.1% | $57.2M +0.3% | $57.1M +0.4% | $56.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $58.9M +1.0% | $58.3M +1.0% | $57.8M +1.2% | $57.1M +0.4% | $56.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
CareDx, Inc
NASDAQ:CDNA
$1.19B
Personalis, Inc.
NASDAQ:PSNL
$851.63M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Evolent Health, Inc.
NYSE:EVH
$539.91M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Emergent BioSolutions Inc.
NYSE:EBS
$429.28M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
SIGA Technologies, Inc.
NASDAQ:SIGA
$309.85M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EMBC generate?
Embecta Corp. (EMBC) reported $1.08B of revenue in fiscal 2025.
Is EMBC profitable?
Embecta Corp. (EMBC) reported $95.40M of net income, with a net margin of 8.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.